13 January 2020 - Imago BioScience today announced that the U.S. FDA has granted fast track designation for the development of bomedemstat (IMG-7289) for the treatment of essential thrombocythemia, a bone marrow disease associated with high platelet counts and potentially catastrophic vascular complications.
Bomedemstat inhibits the enzyme LSD1 (lysine-specific demethylase 1), thus preventing excess platelet and neutrophil production.